Metastasis and angiogenesis: preclinical PET study on hepatocellular carcinoma (He/De) tumor models
The use of animal models to study tumorigenesis and metastatic spread seems crucial to discover novel diagnostic and therapeutic targets that inhibit tumor development and progression. In this study a preclinical metastasis model of hepatocellular carcinoma (He/De) was established to explore metastases formation and related angiogenic processes using positron emission tomography (PET) and angiogenesis specific radiopharmaceuticals. Approximately 8 ± 1 days after the subrenal capsule assay-based generation of the primary, secondary and tertiary transplanted metastatic He/De tumors in Fischer-344 rats, we used [<sup>18</sup>F]FDG, [<sup>68</sup>Ga]Ga-NOTA-c(NGR) and [<sup>68</sup>Ga]Ga-NODAGA-[c(RGD)]<sub>2</sub> for the in vivo PET imaging of tumor development and angiogenesis. [<sup>18</sup>F]FDG displayed the highest level of radioactivity among all investigated tracers. This pattern was consistent across all neoplastic lesions in each of the three transplantations. Comparing the two <sup>68</sup>Ga-labelled probes, the NGR compound showed significantly higher accumulation in the subrenally growing primary/secondary/tertiary He/De tumors (p ≤ 0.05) and related parathymic lymph node metastases (PTLNs, p ≤ 0.01) that could indicate higher expression level for aminopeptidase N/CD13 than for RGD-binding α<sub>v</sub>β<sub>3</sub> integrin. Progressive increase in the [<sup>18</sup>F]FDG, [<sup>68</sup>Ga]Ga-NOTA-c(NGR) and [<sup>68</sup>Ga]Ga-NODAGA-[c(RGD)]<sub>2</sub> uptakes of both the subrenally growing He/De tumors and the PTLNs during the serial transplantations may imply increasing aggressivity. Overall, the currently developed experimental system provides a feasible platform for further investigation of metastatic spread.
Authors
- Alexandra Barkóczi
- Tamás Papp (ORCID: https://orcid.org/0000-0001-6437-0295)
- Péter Károlyi
- István Hajdu (ORCID: https://orcid.org/0000-0001-8008-7756)
- Gábor Opposits (ORCID: https://orcid.org/0000-0002-0065-224X)
- Zita Képes (ORCID: https://orcid.org/0000-0003-2889-8521)
- Ibolya Kálmán-Szabó (ORCID: https://orcid.org/0000-0002-1467-6701)
- István Kertész (ORCID: https://orcid.org/0000-0002-3822-9068)
- György Trencsényi (ORCID: https://orcid.org/0000-0001-6456-6212)
- Ádám Deák (ORCID: https://orcid.org/0000-0001-7516-3152)
- Tamás Sass
- Judit P. Szabó (ORCID: https://orcid.org/0000-0002-0066-5745)
- Renáta Adél Dienes
Institutions
- University of Debrecen (HU)
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2025-07-20
- DOI
- https://doi.org/10.1016/j.ejps.2025.107211
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00